Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Дроспиренонсодержащий контрацептив: лечебные и профилактические аспекты применения
Дроспиренонсодержащий контрацептив: лечебные и профилактические аспекты применения
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Применение комбинированных гормональных контрацептивов – патогенетически обоснованный метод лечения патологических cостояний, ассоциированных с менструальным циклом.
Проведено исследование, целью которого стало изучение эффективности и приемлемости гормонального микродозированного комбинированного орального контрацептива, содержащего 20 мкг этинилэстрадиола и 3 мг дроспиренона (Джес®, Bayer HealthCare Pharmaceuticals, Германия), при лечении женщин, которые страдают от проявлений предменструального синдрома средней и тяжелой степени и дисменореи. В результате лечения выявлено статистически значимое уменьшение интенсивности симптомов предменструального синдрома при отсутствии серьезных неблагоприятных побочных эффектов.
Исследование показало высокую эффективность и приемлемость микродозированного дроспиренонсодержащего комбинированного орального контрацептива в режиме 24/4 при лечении женщин с предменструальным синдромом средней и тяжелой степени тяжести.
Ключевые слова: гормональная контрацепция, дроспиренон, фолиевая кислота, беременность.
The study, the purpose of which was to study the effectiveness and acceptability of hormonal microdosed combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone (Yaz®, Bayer HealthCare Pharmaceuticals, Germany), in the treatment of women who suffer from premenstrual syndrome manifestations and of moderate to severe dysmenorrhea. As a result of treatment revealed a statistically significant reduction of the symptoms of premenstrual syndrome, in the absence of serious adverse effects.
The study showed high efficacy and acceptability of a microdosed drospirenone-containing combined oral contraceptive in 24/4 mode for the treatment of women with premenstrual syndrome secondary to severe.
Key words: hormonal contraception, drospirenone, folic acid, pregnancy.
Проведено исследование, целью которого стало изучение эффективности и приемлемости гормонального микродозированного комбинированного орального контрацептива, содержащего 20 мкг этинилэстрадиола и 3 мг дроспиренона (Джес®, Bayer HealthCare Pharmaceuticals, Германия), при лечении женщин, которые страдают от проявлений предменструального синдрома средней и тяжелой степени и дисменореи. В результате лечения выявлено статистически значимое уменьшение интенсивности симптомов предменструального синдрома при отсутствии серьезных неблагоприятных побочных эффектов.
Исследование показало высокую эффективность и приемлемость микродозированного дроспиренонсодержащего комбинированного орального контрацептива в режиме 24/4 при лечении женщин с предменструальным синдромом средней и тяжелой степени тяжести.
Ключевые слова: гормональная контрацепция, дроспиренон, фолиевая кислота, беременность.
________________________________________________
The study, the purpose of which was to study the effectiveness and acceptability of hormonal microdosed combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone (Yaz®, Bayer HealthCare Pharmaceuticals, Germany), in the treatment of women who suffer from premenstrual syndrome manifestations and of moderate to severe dysmenorrhea. As a result of treatment revealed a statistically significant reduction of the symptoms of premenstrual syndrome, in the absence of serious adverse effects.
The study showed high efficacy and acceptability of a microdosed drospirenone-containing combined oral contraceptive in 24/4 mode for the treatment of women with premenstrual syndrome secondary to severe.
Key words: hormonal contraception, drospirenone, folic acid, pregnancy.
Полный текст
Список литературы
1. Прилепская В.Н. и др. Лечебные возможности современной гормональной контрацепции. Акцент на дроспиренонсодержащее соединение с новым режимом дозирования. Гинекология. 2012; 14 (1): 42–5.
2. Machado RB et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19–30.
3. Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? Drugs 2007; 67 (5): 647–55.
4. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
5. Pinkerton JV. The menstrual cycle–mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24–9.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
7. Kim J, Kim DH, Lee BH et al. Folate intake and the risk of colorectal cancer in a Korean population. Eur J Clin Nutr 2009; 63 (19): 1057–64.
8. Zhang S et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281 (17): 1632–7.
9. D’Anci KE, Rosenberg IH. Folate and brain function in the elderly. Curr Opin Clin Nutr Metab Care 2004; 7 (6): 659–64.
10. Moat SJ et al. High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36 (12): 850–9.
11. Cagnacci A, Cannoletta M, Volpe A. High-dose short-term folate administration modifies ambulatory blood pressure in postmenopausal women.
A placebo-controlled study. Eur J Clin Nutr 2009; 63 (10): 1266–8.
12. Bottiglieri T, Reynolds EH. Folate and neurological disease – basic mechanisms. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 355–72.
13. Morris MS, Jacques P. Folate and neurological function – epidemiological perspective. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 325–46.
14. Arth A et al. Supplement use and other characteristics among pregnant women with a previous pregnancy affected by a neural tube defect – United States, 1997–2009. MMWR Morb Mortal Wkly Rep 2015; 64 (1): 6–9.
15. Hovdenak N, Haram K. Influence of mineral and vitamin supplements on pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 2012; 164 (2): 127–32.
16. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004; 103 (1): 51–6.
17. Holzgreve W et al. Addingfolate to the contraceptive pill: a new concept for the prevention of neural tube defects. J Matern Fetal Neonat Med 2012; 25 (9): 1529–36.
18. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами – новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 22–4.
19. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–5.
20. Choi JH еt al. Contemporary issues surrounding folic Acid fortification initiatives. Prev Nutr Food Sci 2014; 19 (4): 247–60.
21. Talaulikar VS, Arulkumaran S. Folic acid in obstetric practice: a review. Obstet Gynecol Surv 2011; 66 (4): 240–7.
22. Wang Y et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. Eur J Clin Nutr advance online publication, January 28, 2015; doi:10.1038/ejcn. 2014. 295.
23. Hao N et al. Periconceptional folic acid supplementation among pregnant women with epilepsy in a developing country. A retroprospective survey in China. Epilepsy Behav 2015; 22 (44C): 27–34.
2. Machado RB et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19–30.
3. Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? Drugs 2007; 67 (5): 647–55.
4. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
5. Pinkerton JV. The menstrual cycle–mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24–9.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
7. Kim J, Kim DH, Lee BH et al. Folate intake and the risk of colorectal cancer in a Korean population. Eur J Clin Nutr 2009; 63 (19): 1057–64.
8. Zhang S et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281 (17): 1632–7.
9. D’Anci KE, Rosenberg IH. Folate and brain function in the elderly. Curr Opin Clin Nutr Metab Care 2004; 7 (6): 659–64.
10. Moat SJ et al. High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36 (12): 850–9.
11. Cagnacci A, Cannoletta M, Volpe A. High-dose short-term folate administration modifies ambulatory blood pressure in postmenopausal women.
A placebo-controlled study. Eur J Clin Nutr 2009; 63 (10): 1266–8.
12. Bottiglieri T, Reynolds EH. Folate and neurological disease – basic mechanisms. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 355–72.
13. Morris MS, Jacques P. Folate and neurological function – epidemiological perspective. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 325–46.
14. Arth A et al. Supplement use and other characteristics among pregnant women with a previous pregnancy affected by a neural tube defect – United States, 1997–2009. MMWR Morb Mortal Wkly Rep 2015; 64 (1): 6–9.
15. Hovdenak N, Haram K. Influence of mineral and vitamin supplements on pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 2012; 164 (2): 127–32.
16. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004; 103 (1): 51–6.
17. Holzgreve W et al. Addingfolate to the contraceptive pill: a new concept for the prevention of neural tube defects. J Matern Fetal Neonat Med 2012; 25 (9): 1529–36.
18. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами – новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 22–4.
19. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–5.
20. Choi JH еt al. Contemporary issues surrounding folic Acid fortification initiatives. Prev Nutr Food Sci 2014; 19 (4): 247–60.
21. Talaulikar VS, Arulkumaran S. Folic acid in obstetric practice: a review. Obstet Gynecol Surv 2011; 66 (4): 240–7.
22. Wang Y et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. Eur J Clin Nutr advance online publication, January 28, 2015; doi:10.1038/ejcn. 2014. 295.
23. Hao N et al. Periconceptional folic acid supplementation among pregnant women with epilepsy in a developing country. A retroprospective survey in China. Epilepsy Behav 2015; 22 (44C): 27–34.
2. Machado RB et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19–30.
3. Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? Drugs 2007; 67 (5): 647–55.
4. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
5. Pinkerton JV. The menstrual cycle–mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24–9.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
7. Kim J, Kim DH, Lee BH et al. Folate intake and the risk of colorectal cancer in a Korean population. Eur J Clin Nutr 2009; 63 (19): 1057–64.
8. Zhang S et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281 (17): 1632–7.
9. D’Anci KE, Rosenberg IH. Folate and brain function in the elderly. Curr Opin Clin Nutr Metab Care 2004; 7 (6): 659–64.
10. Moat SJ et al. High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36 (12): 850–9.
11. Cagnacci A, Cannoletta M, Volpe A. High-dose short-term folate administration modifies ambulatory blood pressure in postmenopausal women.
A placebo-controlled study. Eur J Clin Nutr 2009; 63 (10): 1266–8.
12. Bottiglieri T, Reynolds EH. Folate and neurological disease – basic mechanisms. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 355–72.
13. Morris MS, Jacques P. Folate and neurological function – epidemiological perspective. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 325–46.
14. Arth A et al. Supplement use and other characteristics among pregnant women with a previous pregnancy affected by a neural tube defect – United States, 1997–2009. MMWR Morb Mortal Wkly Rep 2015; 64 (1): 6–9.
15. Hovdenak N, Haram K. Influence of mineral and vitamin supplements on pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 2012; 164 (2): 127–32.
16. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004; 103 (1): 51–6.
17. Holzgreve W et al. Addingfolate to the contraceptive pill: a new concept for the prevention of neural tube defects. J Matern Fetal Neonat Med 2012; 25 (9): 1529–36.
18. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами – новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 22–4.
19. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–5.
20. Choi JH еt al. Contemporary issues surrounding folic Acid fortification initiatives. Prev Nutr Food Sci 2014; 19 (4): 247–60.
21. Talaulikar VS, Arulkumaran S. Folic acid in obstetric practice: a review. Obstet Gynecol Surv 2011; 66 (4): 240–7.
22. Wang Y et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. Eur J Clin Nutr advance online publication, January 28, 2015; doi:10.1038/ejcn. 2014. 295.
23. Hao N et al. Periconceptional folic acid supplementation among pregnant women with epilepsy in a developing country. A retroprospective survey in China. Epilepsy Behav 2015; 22 (44C): 27–34.
________________________________________________
2. Machado RB et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19–30.
3. Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? Drugs 2007; 67 (5): 647–55.
4. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
5. Pinkerton JV. The menstrual cycle–mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24–9.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
7. Kim J, Kim DH, Lee BH et al. Folate intake and the risk of colorectal cancer in a Korean population. Eur J Clin Nutr 2009; 63 (19): 1057–64.
8. Zhang S et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281 (17): 1632–7.
9. D’Anci KE, Rosenberg IH. Folate and brain function in the elderly. Curr Opin Clin Nutr Metab Care 2004; 7 (6): 659–64.
10. Moat SJ et al. High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36 (12): 850–9.
11. Cagnacci A, Cannoletta M, Volpe A. High-dose short-term folate administration modifies ambulatory blood pressure in postmenopausal women.
A placebo-controlled study. Eur J Clin Nutr 2009; 63 (10): 1266–8.
12. Bottiglieri T, Reynolds EH. Folate and neurological disease – basic mechanisms. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 355–72.
13. Morris MS, Jacques P. Folate and neurological function – epidemiological perspective. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 325–46.
14. Arth A et al. Supplement use and other characteristics among pregnant women with a previous pregnancy affected by a neural tube defect – United States, 1997–2009. MMWR Morb Mortal Wkly Rep 2015; 64 (1): 6–9.
15. Hovdenak N, Haram K. Influence of mineral and vitamin supplements on pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 2012; 164 (2): 127–32.
16. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004; 103 (1): 51–6.
17. Holzgreve W et al. Addingfolate to the contraceptive pill: a new concept for the prevention of neural tube defects. J Matern Fetal Neonat Med 2012; 25 (9): 1529–36.
18. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами – новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 22–4.
19. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–5.
20. Choi JH еt al. Contemporary issues surrounding folic Acid fortification initiatives. Prev Nutr Food Sci 2014; 19 (4): 247–60.
21. Talaulikar VS, Arulkumaran S. Folic acid in obstetric practice: a review. Obstet Gynecol Surv 2011; 66 (4): 240–7.
22. Wang Y et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. Eur J Clin Nutr advance online publication, January 28, 2015; doi:10.1038/ejcn. 2014. 295.
23. Hao N et al. Periconceptional folic acid supplementation among pregnant women with epilepsy in a developing country. A retroprospective survey in China. Epilepsy Behav 2015; 22 (44C): 27–34.
Авторы
А.В.Ледина, В.Н.Прилепская
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.